期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

皮肤T细胞淋巴瘤治疗进展 被引量：3

Novel therapies for cutaneous T-cell lymphoma(CTCL)
下载PDF
导出
摘要 随着对皮肤T细胞淋巴瘤(CTCL)病理发生机制研究的深入,靶向治疗及免疫调节治疗逐渐成为进展期CTCL的重要治疗手段。近年来与之相关的新的治疗方法不断涌现,如维A酸类X受体激动剂、融合毒素、单克隆抗体、Toll样受体激动剂、基因治疗、细胞因子等。与传统药物相比,靶向治疗及免疫调节治疗具有更显著的疗效及较好的安全性,临床应用前景良好。该文对其作一综述。
作者 乔菊 王宝玺
机构地区 中国医学科学院
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2007年第11期739-741,共3页 Journal of Clinical Dermatology
关键词 淋巴瘤 T细胞 皮肤 治疗
分类号 R730.263 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma[J]. J Clin Invest, 2005, 115(4): 798-812.
  • 2Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma[J]. Arch Dermatol, 2002, 138(3): 325- 332.
  • 3Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma [J]. Arch Dermatol, 2001, 137(5): 581-593.
  • 4Duvic M, Hymes K, Heald P, et al, Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase Ⅱ-Ⅲ trial results[J]. J Clin Oncol, 2001, 19(9): 2456-2471.
  • 5Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome[J]. Eur J Cancer, 2006, 42(8): 1014-1030.
  • 6Olsen E, Duvic M, Frankel A, et al. Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma[J]. J Clin Oncol, 2001, 19(2): 376-388.
  • 7Dang NH, Pro B, Hagemeister FB, et al. Phase Ⅱ trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma[J]. Br J Haematol, 2007, 136(3): 439-447.
  • 8Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome[J]. Blood, 2003, 101 (11): 4267-4272.
  • 9Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H[J]. Lancet, 1988, 2(8625): 1394-1399.
  • 10Deeths M J, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream[J]. J Am Acad Dermatol, 2005, 52(2): 275-280.

同被引文献18

  • 1郝北辰,张奕华.具有抗肿瘤作用的维甲酸类化合物的研究进展[J].药学进展,2006,30(2):65-69. 被引量：7
  • 2黄艳.组蛋白去乙酰化酶抑制剂应用前景[J].中国处方药,2006,5(4):57-59. 被引量：5
  • 3严轶东.一种以贝沙罗汀为活性成分的药用组合物及其制备方法、用途:中国,CN1806798A[P].2006.
  • 4Marcus F Boehm,Lin Zhang,Beth Ann Badea,et al.Synthesis and structure acitivity relationships of novel retinoid X receptor-selective retinoids[J].Med Chem,1994,37:2930-2941.
  • 5Carpenter M,Easter W,Wood T.Substituted tetrahydronaphthalens:US,2897237[P].1959.
  • 6张兴锴,孙铁民.治疗皮肤癌新药vorinostat[J].中国药物化学杂志,2007,17(4):268-268. 被引量：10
  • 7Snkajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhib- itors profoundly decrease proliferation of human lymphoid cancer cell line: [ J ]. Exp Hemato1,2005,33 ( 1 ) :53-61.
  • 8Cohen LA, Marks PA, Rifkind RA, et al. Suberoylanilide hydroxamic acid (SAHA), a histone deaeetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors [J] Anticancer Res, 2002, 22 (3) : 1497-1504.
  • 9Gridelli C, Rossi A, Malone P. The potential role of histone deacety- lase inhibitors in the treatment.of non-small-cell lung cancer [ J ]. Criti Oncology Hematology,2008,68 ( 1 ) :29-36.
  • 10Baschnagel A, Russo A, Burgan WE, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic Cell Line Grown In Vitro and as Intracerebral Xenografts [ J ]. Mol Cancer Ther, 2009,8 (6) : 1589-1595.

引证文献3

二级引证文献3

临床皮肤科杂志
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部